News

TipRanks on MSN

C4 Therapeutics initiated with an Overweight at Barclays

Barclays initiated coverage of C4 Therapeutics (CCCC) with an Overweight rating and $8 price target The company’s lead asset, cemsidomide is an ...
Nasdaq

C4 Therapeutics Reports Promising Cemsidomide Data in Multiple Myeloma and Announces Strategic Development Priorities

C4 Therapeutics, Inc. (C4T) announced promising results from the latest data on its investigational drug cemsidomide for treating multiple myeloma, showing a 50% overall response rate (ORR) at the ...

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC ® Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Presentation Date and ...
TipRanks on MSN

C4 Therapeutics announces Biogen had its IND for BIIB142 accepted by FDA

C4 Therapeutics (CCCC) announced that its partner Biogen (BIIB) has had its investigational new drug, IND, application for BIIB142 accepted by the ...